Elanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection

Reuters

07/09

<a href="https://laohu8.com/S/ELAN">Elanco Animal Health Inc</a>. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection

Elanco Animal Health Inc. has received approval from the U.S. Department of Agriculture (USDA) for its TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine. This vaccine offers broad respiratory protection against the H3N2 and H3N8 strains, making it the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine available with such comprehensive coverage. With 100% virus neutralization against 33 current field isolates and zero lung lesions observed in vaccinated dogs post H3N2 challenge, TruCan Ultra CIV completes Elanco's Tru Portfolio of vaccines. This approval underscores Elanco's commitment to providing innovative animal health solutions, enhancing the health and happiness of pets and their owners.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DE25259) on July 09, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2550313637"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550313637\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550313637?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550313637","market":"us","top_or_hot":-1,"title":"Elanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ELAN\">Elanco Animal Health Inc</a>. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ELAT\">Elanco Animal Health</a> Inc. has received approval from the U.S. Department of Agriculture (USDA) for its TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine. This vaccine offers broad respiratory protection against the H3N2 and H3N8 strains, making it the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine available with such comprehensive coverage. With 100% virus neutralization against 33 current field isolates and zero lung lesions observed in vaccinated dogs post H3N2 challenge, TruCan Ultra CIV completes Elanco's Tru Portfolio of vaccines. This approval underscores Elanco's commitment to providing innovative animal health solutions, enhancing the health and happiness of pets and their owners.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DE25259) on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-09 20:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ELAN\">Elanco Animal Health Inc</a>. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ELAT\">Elanco Animal Health</a> Inc. has received approval from the U.S. Department of Agriculture (USDA) for its TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine. This vaccine offers broad respiratory protection against the H3N2 and H3N8 strains, making it the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine available with such comprehensive coverage. With 100% virus neutralization against 33 current field isolates and zero lung lesions observed in vaccinated dogs post H3N2 challenge, TruCan Ultra CIV completes Elanco's Tru Portfolio of vaccines. This approval underscores Elanco's commitment to providing innovative animal health solutions, enhancing the health and happiness of pets and their owners.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DE25259) on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4561","symbol_name":"索罗斯持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL4htnFm:1","article_id":"2550313637","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550313637","pubTimestamp":1752064039,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Elanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection. Elanco Animal Health Inc. has received approval from the U.S. Department of Agriculture  for its TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine. This vaccine offers broad respiratory protection against the H3N2 and H3N8 strains, making it the only  mL bivalent Canine Influenza Virus  vaccine available with such comprehensive coverage. With 100% virus neutralization against 33 current field isolates and zero lung lesions observed in vaccinated dogs post H3N2 challenge, TruCan Ultra CIV completes Elanco's Tru Portfolio of vaccines. This approval underscores Elanco's commitment to providing innovative animal health solutions, enhancing the health and happiness of pets and their owners.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4561":"索罗斯持仓","BK4007":"制药","ELAN":"Elanco Animal Health Inc"},"translate_title":"Elanco Animal Health Inc.获得美国农业部批准TruCan Ultra CIV犬流感疫苗，增强狗的呼吸保护","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAN":0.9},"content_text":"Elanco Animal Health Inc. Receives USDA Approval for TruCan Ultra CIV Canine Influenza Vaccine, Enhancing Dog Respiratory Protection\n    \n\nElanco Animal Health Inc. has received approval from the U.S. Department of Agriculture (USDA) for its TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine. This vaccine offers broad respiratory protection against the H3N2 and H3N8 strains, making it the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine available with such comprehensive coverage. With 100% virus neutralization against 33 current field isolates and zero lung lesions observed in vaccinated dogs post H3N2 challenge, TruCan Ultra CIV completes Elanco's Tru Portfolio of vaccines. This approval underscores Elanco's commitment to providing innovative animal health solutions, enhancing the health and happiness of pets and their owners.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elanco Animal Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DE25259) on July 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}